Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldurazyme in Chinese MPS I patients
NCT05134571Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2021
- Primary completion
- Jul 2023
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of laronidase in mucopolysaccharidosis type I, sponsored by Sanofi. Primary endpoints: Adverse Events at 27 weeks, Potentially Clinically Significant Abnormality at 27 weeks and 1 more. Started Oct 2021; status: completed.
02
Drugs
laronidase
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on NCT05134571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05134571.